Regulatory compliance – Page 57

Backdated documentation detected during record archival – GDP remediation CAPA

Addressing the Issue of Backdated Documentation in Record Archival: A Comprehensive Playbook In the fast-paced world of pharmaceutical manufacturing, maintaining documentation integrity is crucial for compliance and operational efficiency. The…

Inadequate evidence during inspection during FDA/EMA inspection – preventing escalation to warning letter

Mitigating Inadequate Evidence During FDA/EMA Inspections to Prevent Escalation Pharmaceutical manufacturing organizations frequently find themselves navigating rigorous FDA and EMA inspections, where the adequacy of evidence can determine the trajectory…

Incomplete contemporaneous recording during audit trail review – evidence pack inspectors expect

Tackling Incomplete Contemporaneous Recording During Audit Trail Review In the process of pharmaceutical manufacturing, incomplete contemporaneous recording can lead to serious compliance issues during regulatory audits. This article serves as…

Team unprepared for interviews during FDA/EMA inspection – CAPA closure verification

Addressing Team Readiness for Interviews During FDA/EMA Inspections: A Structured Playbook In the highly regulated world of pharmaceutical manufacturing, the lack of interview preparedness among team members during FDA or…

GDP errors in batch records during record archival – ALCOA+ gap analysis

Managing GDP Errors in Batch Records During Archival: A Comprehensive Playbook In today’s highly regulated pharmaceutical environment, the accuracy and integrity of batch records during archival are paramount. GDP errors…

CAPA follow-up weak during WHO audit – CAPA closure verification

Strengthening CAPA Follow-up for WHO Audits: A Practical Guide During audits, particularly those conducted by the World Health Organization (WHO), weaknesses in the Corrective and Preventive Action (CAPA) process can…

GDP errors in batch records during deviation investigation – GDP remediation CAPA

Understanding and Remediating GDP Errors in Batch Records During Deviation Investigations In pharmaceutical manufacturing, Good Documentation Practices (GDP) are essential for ensuring traceability, data integrity, and regulatory compliance. However, errors…

Inspection readiness untested before regulatory inspection – question-and-answer handling techniques

Strategies for Ensuring Inspection Readiness Before Regulatory Scrutiny Pharmaceutical manufacturing facilities often face unpredictable regulatory inspections that can impact their operational integrity. Lack of adequate preparation for these inspections can…

Tag: Regulatory compliance

Backdated documentation detected during record archival – GDP remediation CAPA

Inadequate evidence during inspection during FDA/EMA inspection – preventing escalation to warning letter

Incomplete contemporaneous recording during audit trail review – evidence pack inspectors expect

Team unprepared for interviews during FDA/EMA inspection – CAPA closure verification

GDP errors in batch records during record archival – ALCOA+ gap analysis

CAPA follow-up weak during WHO audit – CAPA closure verification

GDP errors in batch records during deviation investigation – GDP remediation CAPA

Inspection readiness untested before regulatory inspection – question-and-answer handling techniques

Backdated documentation detected during inspection review – evidence pack inspectors expect

Mock audit findings ignored during WHO audit – CAPA closure verification

GDP errors in batch records during inspection review – ALCOA+ gap analysis

Inspection responses delayed before regulatory inspection – preventing escalation to warning letter